Curis Stock Price, News & Analysis

Curis, Inc. (NASDAQ: CRIS) reported its Q2 2021 financial results, showing a net loss of $10.8 million ($0.12/share), compared to a loss of $6.7 million in Q2 2020. Revenues slightly decreased to $2.3 million, primarily from royalties. The company continues to advance its pipeline, notably the IRAK4 inhibitor CA-4948, demonstrating positive data in clinical trials for AML/MDS patients. Operating expenses rose to $12.9 million due to increased R&D costs. Curis holds $160.7 million in cash, sufficient to fund operations into 2024.

Curis, Inc. (NASDAQ: CRIS) announced it will release its second quarter 2021 financial results on August 3, 2021, after US market close. A conference call will be held at 4:30 pm ET the same day. The company is focused on developing innovative therapeutics for cancer treatment, including collaborations on several clinical trials. Notably, CA-4948 is currently in Phase 1/2 trials for non-Hodgkin lymphoma and has received Orphan Drug Designation for acute myeloid leukemia from the FDA.

Curis, Inc. (NASDAQ: CRIS) announced on July 1, 2021, the approval of inducement stock options for 259,550 shares to fifteen new employees. These stock options have an exercise price equal to the closing price on the grant date, vesting over four years. Curis develops cancer therapeutics, including collaborations on various treatments such as the IRAK4 inhibitor CA-4948, currently in clinical trials. This grant is intended to incentivize new hires and enhance employee retention.

Curis, Inc. (NASDAQ: CRIS) will be added to the Russell 2000®, 3000®, and Microcap® indexes, effective June 28, 2021. This inclusion recognizes Curis's market capitalization among the largest U.S. stocks, enhancing its visibility within the investment community. The Russell indexes serve as benchmarks for approximately $10.6 trillion in assets, indicating Curis's increased accessibility to institutional investors. CEO James Dentzer expressed enthusiasm for this milestone, highlighting the importance of index membership for overall growth and investor relations.

Curis, Inc. (NASDAQ: CRIS) announced positive updates from its Phase 1/2 trial of CA-4948, an IRAK4 kinase inhibitor, at the EHA 2021 Congress. The trial targets patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Key findings show effective dose at 300 mg BID, with significant hematologic recovery and objective responses in patients with spliceosome or FLT3 mutations. CA-4948 also demonstrated synergistic activity in preclinical studies when combined with azacitidine and venetoclax. The company plans to initiate combination studies later this year.

Curis (NASDAQ: CRIS) announced a virtual KOL event on June 11, 2021, to discuss progress on CA-4948, a first-in-class IRAK4 kinase inhibitor. The event will include updated data from the Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), initially presented at the European Hematology Association 2021 Virtual Congress. Curis CEO James Dentzer and Dr. Guillermo Garcia-Manero from MD Anderson Cancer Center will lead the discussion, with a Q&A session to follow. A live webcast will be available on Curis' website.

Curis, Inc. (NASDAQ: CRIS) announced a virtual symposium titled "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond", occurring on June 18, 2021. The event will feature discussions on the emerging checkpoint molecule VISTA, its implications in various diseases, and ongoing development programs, including Curis's anti-VISTA antibody, CI-8993, currently in clinical trials. Notable speakers include Dr. Randolph Noelle and Dr. Padmanee Sharma. Attendees will explore topics such as checkpoint therapy, VISTA's role in the tumor microenvironment, and advances in clinical development.

Curis, a biotechnology company specializing in cancer therapeutics, announced that its CEO, James Dentzer, will participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 3:00 p.m. ET. The event will be available via live webcast on Curis' investor website, with a replay for 90 days post-event. Curis is known for its research in immuno-oncology and precision oncology, including ongoing trials for CA-4948, targeting various forms of cancer.

Curis, Inc. (NASDAQ: CRIS) reported its Q1 2021 results, marking a net loss of $9.9 million or $0.11 per share. Revenues declined to $2.2 million from $2.7 million in Q1 2020. Operational highlights include progress on CA-4948, which expanded into new clinical trials, receiving Orphan Drug designation from the FDA for AML and MDS, and promising early results in ongoing studies. Cash reserves stood at $168.4 million, expected to sustain operations into 2024. The company plans to share more clinical data at the EHA Congress and future trials in the second half of 2021.